BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.20B

EPS-6.8600

P/E Ratio-1.65

Earnings Date08/10/2026

bhvn

Other Current Liabilities

Last Annual Value

104.29M

3-Year CAGR

93%

5-Year CAGR

69%

10-Year CAGR

36%

Adjust for Inflation

Biohaven Ltd. Competitors Analysis of Other Current Liabilities

BHVN · NYSE

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Biohaven Ltd. NYSE:BHVN	104.29M	N/A	N/A	N/A
Intellia Therapeutics, Inc. NASDAQ:NTLA	49.86M	93.4%	19.6%	31.6%
Immunome, Inc. NASDAQ:IMNM	41.65M	103.0%	83.2%	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	31.01M	86.0%	141.6%	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	9.67M	45.9%	N/A	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	54.30M	119.7%	N/A	N/A
Xeris Biopharma Holdings, Inc. NASDAQ:XERS	100.27M	24.9%	31.4%	71.0%
Celldex Therapeutics, Inc. NASDAQ:CLDX	48.26M	129.6%	98.8%	6.2%

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

HIDDEN

Intrinsic Value

Current Price: $11.35

Related Guides

Blog Categories

Continue your BHVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.